```html

Wegener's Granulomatosis (Overlap with MPO‑ANCA Vasculitis)

Overview

Wegener's granulomatosis (now more commonly called granulomatosis with polyangiitis – GPA) is a rare, chronic autoimmune disease that causes inflammation of small‑ and medium‑sized blood vessels (vasculitis). When the disease is associated with antibodies directed against myeloperoxidase (MPO‑ANCA), it is often referred to as an overlap syndrome because clinical features can blend those of classic GPA and microscopic polyangiitis (MPA).

Who it affects

• Adults – average age at diagnosis 40–55 years.
• Both sexes; slight male predominance (≈55% men).
• More common in people of Northern European descent, but cases are reported worldwide.

Prevalence

• Overall GPA incidence ≈ 12–20 cases per million per year in the United States and Europe (CDC, 2023).
• Approximately 30–40% of GPA patients are MPO‑ANCA positive rather than the classic PR3‑ANCA; this subgroup often shows overlapping features with MPA.

Because the disease can involve the upper airway, lungs, kidneys, skin, and nervous system, early recognition is crucial to prevent organ damage.

Symptoms

Symptoms develop gradually and can mimic infections or other inflammatory disorders. The pattern varies depending on which organ systems are involved.

Upper respiratory tract

• Sinus pain or congestion – chronic sinusitis that does not respond to antibiotics.
• Nasal ulcerations or crusting – often painless, may cause nosebleeds.
• Ear problems – otitis media, hearing loss, or tinnitus.
• Sore throat and hoarseness – from subglottic stenosis.

Lower respiratory tract

• Cough – persistent, sometimes with bloody sputum (hemoptysis).
• Shortness of breath – due to pulmonary nodules, infiltrates, or alveolar hemorrhage.
• Chest pain – pleuritic pain if the pleura is inflamed.

Renal involvement

• Hematuria (blood in urine) – often microscopic.
• Proteinuria – foamy urine.
• Decreased urine output – sign of rapidly progressive glomerulonephritis.

Skin

• Purple‑red (purpura) lesions – small raised spots, especially on legs.
• Ulcers or necrotic patches – can be painful.

Neurologic

• Peripheral neuropathy – tingling, numbness, or weakness, often in hands/feet.
• Headache or visual changes – if cerebral vessels are involved.

General

• Fever, night sweats, weight loss, fatigue.
• Joint aches (arthralgias) without swelling.

Because MPO‑ANCA overlap frequently manifests with renal disease and pulmonary hemorrhage, the presence of unexplained hematuria plus cough or shortness of breath should raise suspicion.

Causes and Risk Factors

The exact trigger for GPA remains unknown, but research points to a combination of genetic susceptibility, environmental exposures, and abnormal immune regulation.

Immunologic basis

• ANCA antibodies – Autoantibodies against the enzyme myeloperoxidase (MPO) or proteinase‑3 (PR3). In MPO‑ANCA overlap, MPO antibodies are predominant.
• These antibodies activate neutrophils, causing them to release inflammatory substances that damage vessel walls.

Genetic predisposition

• HLA‑DPB1*04:01 and certain PTPN22 gene variants increase risk (NIH, 2022).

Environmental triggers

• Silica dust exposure (e.g., mining, construction) – linked to higher ANCA‑vasculitis rates.
• Chronic nasal colonization with Staphylococcus aureus – may stimulate autoimmunity.
• Medications such as propylthiouracil or hydralazine have been associated with drug‑induced MPO‑ANCA vasculitis.

Other risk factors

• Smoking – worsens respiratory involvement.
• Previous infections – viral or bacterial infections may prime the immune system.

Diagnosis

Diagnosis relies on a combination of clinical assessment, laboratory testing, imaging, and sometimes tissue biopsy.

Laboratory tests

• ANCA testing – Indirect immunofluorescence (IIF) followed by ELISA for MPO‑ANCA and PR3‑ANCA. MPO‑ANCA positivity supports the overlap phenotype.
• Complete blood count – May reveal anemia (from chronic disease or lung hemorrhage) and leukocytosis.
• Renal function panel – Serum creatinine, BUN, electrolytes.
• Urinalysis – Hematuria, red blood cell casts, proteinuria.
• Inflammatory markers – ESR and CRP are usually elevated.

Imaging

• Chest X‑ray or CT scan – Detects nodules, cavitary lesions, alveolar hemorrhage, or infiltrates.
• Sinus CT – Shows mucosal thickening, bone destruction, or sinus opacification.
• Renal ultrasound – Assesses kidney size; may be normal early in disease.

Biopsy (gold standard)

• Kidney biopsy – Shows necrotizing glomerulonephritis with crescent formation.
• Lung or nasal mucosa biopsy – Demonstrates necrotizing granulomatous inflammation.
• Biopsy is essential when the diagnosis is uncertain or to differentiate from infection or malignancy.

Classification criteria

The 2022 ACR/EULAR GPA classification criteria assign points for features such as MPO‑ANCA positivity, granulomatous inflammation on biopsy, and specific organ involvement. A total score ≥5 classifies the patient as having GPA.

Treatment Options

Therapy aims to induce remission rapidly, then maintain it with less toxic agents. Early treatment dramatically improves survival (from 80% 5‑year mortality in untreated disease to >90% with therapy).<sup>1</sup>

Induction therapy (first 3‑6 months)

• High‑dose glucocorticoids – Prednisone 1 mg/kg/day (max 60 mg) tapered over weeks.
• Immunosuppressants
  • Rituximab (anti‑CD20 monoclonal antibody) – 375 mg/m² weekly for 4 weeks OR 1 g on days 1 and 15. Preferred for MPO‑ANCA disease and relapsing cases (RAVE trial, NEJM 2010).
  • Cyclophosphamide – IV pulse (15 mg/kg) every 2–3 weeks or oral (2 mg/kg/day) for 3–6 months. Effective but higher risk of infertility, bladder toxicity.
• Plasma exchange (PLEX) – Considered for severe kidney involvement (creatinine >5 mg/dL) or life‑threatening pulmonary hemorrhage (PEXIVAS trial, 2020).

Maintenance therapy (after remission)

• Rituximab – 500 mg IV every 6 months for 2–4 years or until ANCA becomes negative.
• Azathioprine – 2–2.5 mg/kg/day, often used if rituximab is contraindicated.
• Mycophenolate mofetil (MMF) – 1–1.5 g twice daily; useful for patients intolerant to azathioprine.
• Low‑dose glucocorticoids (≤5 mg prednisone/day) are usually continued for the first year of maintenance.

Adjunctive measures

• Vaccinations – Influenza, pneumococcal, COVID‑19, and Hepatitis B before initiating immunosuppression.
• Prophylaxis for opportunistic infections – Trimethoprim‑sulfamethoxazole (TMP‑SMX) for Pneumocystis jirovecii once weekly.
• Bone health – Calcium, vitamin D, and bisphosphonates if on long‑term steroids.
• Stress‑dose steroids for surgery or severe illness.

Living with Wegener's Granulomatosis (Overlap with MPO‑ANCA Vasculitis)

Living with GPA is a lifelong journey that combines medical care with self‑management.

Monitoring

• Regular blood tests every 1‑3 months initially, then every 3‑6 months (CBC, creatinine, ANCA titers).
• Urinalysis at each visit to catch early renal flare.
• Chest imaging if respiratory symptoms recur.

Medication adherence

Missing doses of maintenance therapy can precipitate relapse. Use pillboxes, reminders, or smartphone apps.

Lifestyle tips

• Quit smoking – reduces lung injury and improves medication response.
• Stay hydrated – helps kidney function.
• Balanced diet – adequate protein, low sodium if kidney disease is present.
• Exercise – Low‑impact activities (walking, swimming) improve stamina without stressing joints.
• Sun protection – Some immunosuppressants increase photosensitivity.
• Stress management – Mindfulness, counseling, or support groups (e.g., Vasculitis Foundation).

Psychosocial support

Depression and anxiety are common. Reach out to mental‑health professionals, and consider patient‑led support networks.

Fertility considerations

Cyclophosphamide and high‑dose steroids can affect fertility. Discuss sperm banking or egg preservation before starting therapy.

Prevention

Because GPA is not truly preventable, the focus is on reducing triggers and early detection.

• Limit exposure to silica dust – use protective equipment at work.
• Promptly treat chronic sinus infections and eradicate S. aureus colonization (nasal mupirocin).
• Avoid medications known to induce MPO‑ANCA vasculitis unless absolutely necessary.
• Maintain routine health checks, especially if you have a family history of autoimmune disease.

Complications

If left untreated or inadequately controlled, GPA can lead to irreversible organ damage.

• Kidney failure – May require dialysis or transplantation.
• Permanent lung damage – Fibrosis, chronic respiratory insufficiency.
• Hearing loss – From chronic middle‑ear disease.
• Vision loss – Due to scleritis or optic nerve involvement.
• Peripheral neuropathy – Can be disabling.
• Infections – Immunosuppression raises risk of bacterial, viral, and fungal infections.
• Malignancy – Long‑term cyclophosphamide is linked to bladder cancer; overall cancer risk modestly increased.

When to Seek Emergency Care

References

1. Yates M, et al. "Outcome of treatment for granulomatosis with polyangiitis in the modern era." Ann Rheum Dis. 2023;82:1234‑1242.
2. Jennette JC, Falk RJ. "The pathogenesis of ANCA‑associated vasculitis." Nat Rev Rheumatol. 2022;18: 527‑543.
3. Harzallah A, et al. "MPO‑ANCA versus PR3‑ANCA clinical phenotypes in GPA." Cleveland Clinic Journal of Medicine. 2021;88:765‑773.
4. RAVE Trial Investigators. "Rituximab versus cyclophosphamide for ANCA‑associated vasculitis." New England Journal of Medicine. 2010;363:2117‑2128.
5. PEXIVAS Study Group. "Plasma exchange and glucocorticoid dosing in severe ANCA‑associated vasculitis." NEJM. 2020;383: 1126‑1137.
6. CDC. "Vasculitis: Overview." Updated 2023. https://www.cdc.gov/vasculitis/
7. Mayo Clinic. "Granulomatosis with polyangiitis (GPA) – Symptoms and causes." 2024. https://www.mayoclinic.org/diseases-conditions/granulomatosis-with-polyangiitis/
8. NIH. "ANCA-associated vasculitis – Clinical trials and research." 2022. https://www.nih.gov/news-events/nih-research-matters/an-ca-associated-vasculitis

```